Parkinson disease: An update

Neurologist

Volumn 10, Issue 4, 2004, Pages 185-194

  Frucht, Steven J ^a  

^a Department of Orthopaedic Surgery   (United States)

Author keywords

Parkinson disease; Pharmacotherapy

Indexed keywords

AMANTADINE; BENZATROPINE; BIPERIDEN; BROMOCRIPTINE MESILATE; CARBEX; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; FLUDROCORTISONE; LEVODOPA; MIDODRINE; NEUROLEPTIC AGENT; PAROXETINE; PERGOLIDE; PERGOLIDE MESILATE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; ROPINIROLE; SELEGILINE; SERAQEUL; SILDENAFIL; TOLCAPONE; TRIHEXYPHENIDYL;

ALLERGY; AMNESIA; ASTHENIA; CARDIOMYOPATHY; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIZZINESS; DRY EYE; DYSKINESIA; EDEMA; ERECTILE DYSFUNCTION; HALLUCINATION; HUMAN; HYPERSALIVATION; HYPERTENSION; HYPOTENSION; INSOMNIA; LEUKOPENIA; LIVEDO RETICULARIS; LIVER TOXICITY; MYOCARDITIS; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STANDING; URINARY HESITANCY; VISUAL IMPAIRMENT;

ADULT; AGED; ANTIPARKINSON AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; UNITED STATES;

EID: 3242683257     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000131146.08278.a5     Document Type: Review

References (37)

1. Birkmayer W, Hornykiewicz. Der L-3,4-dioxyphenylalanin (Dopa)-effekt: bei der Parkinson-akinese. Wein Klin Wschr. 1961;73:787.
2. Cotzias GC, Van Woert MH, Schiffer L. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276:374.
3. Yahr MR, Duvoisin RC, Hoehn MM, et al. L-23-4-dihydroxyphenylalanine (L-Dopa); its clinical effects in parkinsonism. Trans Am Neurol Assoc. 1968;93:56.
4. Siderowf A. Parkinson's disease: clinical features, epidemiology and genetics. Neurol Clin. 2001;19:565-578.
5. Hughes AJ, Daniel SE, Blankson S, et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993;50:140-148.
6. Thornton JE, Stahl SM. Case report of tardive dyskinesia and parkinsonism associated with amoxapine therapy. Am J Psychiatry. 1984;141: 704-705.
7. Sasso E, Delsoldato S, Negrotti A, et al. Reversible valproate-induced extrapyramidal disorders. Epilepsia. 1994;35:391-393.
8. Hughes AJ, Daniel SE, Ben-Shlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861-870.
9. Wenning Gk, Scherfler C, Granat R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathologic study. J Neurol Neurosurg Psychiatry. 1999;67:620-623.
10. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet. 1998;352:958.
11. th Edition. Medical Economics Company; 2002.
12. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA 1997;278: 125-130.
13. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology. 1997;49: 1060-1065.
14. Pogarell O, Gasser T, Van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomized, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72:713-720.
15. Marek K, Seibyl J, Shoulson I, et al. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653-1661.
16. Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol. 1998;21:101-107.
17. Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord. 1998;13:46-51.
18. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology. 1998;51:1057-1062.
19. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J. Med. 2000;342:1484-1491.
20. Hauser RA, Gauge L, Anderson WM, et al. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord. 2000;15:658-663.
21. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908-1910.
22. Frucht SJ, Greene PE, Fahn S. Sleep episodes in Parkinson's disease: a wake-up call. Mov Disord. 2000;15:601-603.
23. Nutt JG. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 2000;55:S33-37.
24. Piccini P, Brooks DJ, Korpela K, et al. The catechol-O-methyltranserase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;68:589-594.
25. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2001;70:734-738.
26. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999; 340:757-763.
27. The French Clozapine Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet. 1999;353:2041-2042.
28. Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 1999;14:484-487.
29. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double blind, placebo-controlled study with midodrine. Am J Med. 1993;95:38-48.
30. Quinn N, Illas A, Lhermitte F, et al. Bromocriptine and domperidone in the treatment of Parkinson's disease. Neurology. 1981;31:662-667.
31. Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord. 2000;25:305-308.
32. Hussain IF, Brady CM, Swinn MJ, et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001;71:371-374.
33. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology. 2000;55:1216-1218.
34. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new Mao-B inhibitor for the treatment of Parkinson's disease: a double-blind as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000;23:324-330.
35. Djaldetti R, Inzelberg R, Giladi N, et al. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord. 2002;17:297-302.
36. Knutsen LJ, Weiss SM. KW-6002 (Kyowa Hakko Kogyo). Curr Opin Invest Drugs. 2001;2:668-673.
37. Zurn AD, Widmer HR, Aebischer P. Sustained delivery of GDNF: towards a treatment for Parkinson's disease. Brain Res Brain Res Rev. 2001;36:222-229.